As
an essential metal ion and an efficient relaxation
agent, Mn2+ holds a great promise to replace Gd3+ in magnetic
resonance imaging (MRI) contrast agent applications, if its stable
and inert complexation can be achieved. Toward this goal, four pyridine
and one carboxylate pendants have been introduced in coordinating
positions on the bispidine platform to yield ligand L3.
Thanks to its rigid and preorganized structure and perfect size match
for Mn2+, L3 provides remarkably high thermodynamic
stability (log K
MnL = 19.47), selectivity
over the major biological competitor Zn2+ (log(K
MnL/K
ZnL) = 4.4), and kinetic
inertness. Solid-state X-ray data show that [MnL3(MeOH)](OTf)2 has an unusual eight-coordinate structure with a coordinated
solvent molecule, in contrast to the six-coordinate structure of [ZnL3](OTf), underlining that the coordination cavity is perfectly
adapted for Mn2+, while it is too large for Zn2+. In aqueous solution, 17O NMR data evidence one inner
sphere water and dissociatively activated water exchange (k
ex
298 = 13.5 × 107 s–1) for MnL3. Its water proton relaxivity
(r
1 = 4.44 mM–1 s–1 at 25 °C, 20 MHz) is about 30% higher than values
for typical monohydrated Mn2+ complexes, which is related
to its larger molecular size; its relaxation efficiency is similar
to that of clinically used Gd3+-based agents. In
vivo MRI experiments realized in control mice at 0.02 mmol/kg
injected dose indicate good signal enhancement in the kidneys and
fast renal clearance. Taken together, MnL3 is the first
chelate that combines such excellent stability, selectivity, inertness
and relaxation properties, all of primary importance for MRI use.